CC-223 and Ketoconazole Drug-Drug Interaction Study

Summary

This is a single-center open-label study to compare how CC-223 (the study drug being investigated) interacts with the drug ketoconazole.

Timeline

Start

2013-07-01

Primary completion

2013-08-01

Completion

2013-08-01

Publications

• Background Tong Z, Narayanan R, Atsriku C, Nissel J, Li Y, Liu H, Wang X, Surapaneni S. Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70. doi: 10.1080/00498254.2018.1424377. Epub 2018 Jan 17.

Drugs

Indications

No indication recorded.